Other Events ·
Valion Bio's Velocity Bioworks completes initial feasibility evaluation of LarmorBio’s BioScan-NMR platform
TIVCValion Bio, Inc.
On October 15, 2026, Valion Bio announced that its wholly owned CDMO subsidiary, Velocity Bioworks, completed an initial feasibility evaluation of LarmorBio’s BioScan-NMR™ platform. The evaluation demonstrated a strong correlation between NMR measurements and optical density at 600 nm (OD600), supporting the potential for continuous, real-time, non-invasive monitoring of microbial growth during fermentation processes. This milestone validates early-stage proof-of-concept data aimed at reducing reliance on invasive sampling and lowering manufacturing costs. Valion Bio is a biopharmaceutical company developing biologics that activate innate immune pathways, with lead candidates Entolimod and Entolasta targeting acute radiation syndrome and oncology supportive care.